BRIEF-Eli Lilly down in premarket after Alzheimer's treatment update

NEW YORK Wed Dec 12, 2012 7:37am EST

NEW YORK Dec 12 (Reuters) - Eli Lilly and Co : * Down 3.2 percent to $49 in premarket after the company said it plans to conduct a big new trial of its experimental Alzheimer's disease treatment among patients with mild symptoms but did not plan to seek U.S. apporval at this time

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.